Identification of non-tuberculous mycobacteria: utility of the GenoType Mycobacterium CM/AS assay compared with HPLC and 16S rRNA gene sequencing
1 Centre for Infectious Diseases and Microbiology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney, Australia 2 Western Clinical School, University of Sydney, Sydney, Australia Correspondence Gwendolyn L. Gilbert l.gilbert{at}usyd.edu.au Received October 22, 2008 Acce...
Saved in:
Published in | Journal of medical microbiology Vol. 58; no. 7; pp. 900 - 904 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Reading
Soc General Microbiol
01.07.2009
Society for General Microbiology |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | 1 Centre for Infectious Diseases and Microbiology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney, Australia
2 Western Clinical School, University of Sydney, Sydney, Australia
Correspondence Gwendolyn L. Gilbert l.gilbert{at}usyd.edu.au
Received October 22, 2008
Accepted March 27, 2009
Non-tuberculous mycobacteria (NTM) causing clinical disease have become increasingly common and more diverse. A new reverse line probe assay, GenoType Mycobacterium CM/AS (Hain Lifescience), was evaluated for identification of a broad range of NTM. It was compared with phenotypic (HPLC) and molecular (DNA probes, in-house real-time multiplex species-specific PCR, 16S rRNA gene PCR and sequencing) identification techniques, which together provided the reference gold standard. A total of 131 clinical isolates belonging to 31 Mycobacterium species and 19 controls, including 5 non- Mycobacterium species, was used. Concordant results between the GenoType Mycobacterium assay and the reference identification were obtained in 119/131 clinical isolates (90.8 %). Identification of Mycobacterium abscessus and Mycobacterium lentiflavum by the assay was problematic. The GenoType Mycobacterium assay enables rapid identification of a broad range of potentially clinically significant Mycobacterium species, but some species require further testing to differentiate or confirm ambiguous results.
Present address: Infection Control Program, University of Geneva Hospitals, Geneva, Switzerland. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0022-2615 1473-5644 |
DOI: | 10.1099/jmm.0.007484-0 |